The cytotoxicity and efficacy of CAR T cells are enhanced through the combination with specific miRNAs, as demonstrated by their ability to target EGFRvIII for glioblastoma or HER2 for cancer therapy (Tang et al., 2022). This evidence concerns the gene ERBB2 and cancer.